Moderna, Inc. vs Under Armour Inc Class A — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Moderna, Inc. is far larger — about 38× Under Armour Inc Class A's market cap, and Moderna, Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Under Armour Inc Class A for 99 Days on average.
| MRNA | UAA | |
|---|---|---|
Market Cap | $78.65B | $2.07B |
Volume | 37,373,437 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $225.00 | $8.14 |
52-Week Low | $22.36 | $4.17 |
Typical Hold Time | 59 Days | 99 Days |
Enterprise Value | $74.80B | $3.05B |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and ROE (-29.82%) despite beating Q2 2026 EPS estimates. Recent news highlights the company's brand transformation efforts amid softer demand, with management maintaining profitability outlook despite revenue cuts.
The stock presents a high-risk opportunity with analyst consensus pointing to 18.6% upside to the $5.79 price target. Key risks include persistent revenue weakness, negative cash flow trends, and competitive pressures. The 27% buy rating suggests cautious optimism, but investors need clear evidence of sustainable margin improvement and revenue stabilization for meaningful upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →